Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $10.0 million.

  • Rxo's Other Accumulated Expenses fell 6153.85% to $10.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 million, marking a year-over-year decrease of 6153.85%. This contributed to the annual value of $10.0 million for FY2025, which is 6153.85% down from last year.
  • Latest data reveals that Rxo reported Other Accumulated Expenses of $10.0 million as of Q4 2025, which was down 6153.85% from $12.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Other Accumulated Expenses registered a high of $26.0 million during Q4 2024, and its lowest value of $5.0 million during Q3 2022.
  • Over the past 5 years, Rxo's median Other Accumulated Expenses value was $12.0 million (recorded in 2024), while the average stood at $11.9 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 28333.33% in 2024, then crashed by 6153.85% in 2025.
  • Quarter analysis of 5 years shows Rxo's Other Accumulated Expenses stood at $6.0 million in 2021, then surged by 133.33% to $14.0 million in 2022, then fell by 7.14% to $13.0 million in 2023, then surged by 100.0% to $26.0 million in 2024, then plummeted by 61.54% to $10.0 million in 2025.
  • Its Other Accumulated Expenses was $10.0 million in Q4 2025, compared to $12.0 million in Q3 2025 and $13.0 million in Q2 2025.